Psychopharmacology

Pasithea Therapeutics Adds Esketamine Nasal Spray to its Clinic Offerings in the U.K.

Retrieved on: 
Tuesday, November 23, 2021
Patient, CEO, Review, Behavior, Forward-looking statement, Company, Suicidal ideation, Health, Psychopharmacology, MDD, Ketamine, SEC, Program, KTTA, Psychiatry, Depression, Lists of diseases, TRD, Nasdaq, Grammatical mood, Research, MIAMI, GLOBE, Biotechnology, N, Pasithea (Charites), Therapy, NMDA, CIII, Pharmaceutical industry

This is an important milestone for our U.K. clinics and their patients, stated Dr. Tiago Reis Marques, CEO of Pasithea Therapeutics.

Key Points: 
  • This is an important milestone for our U.K. clinics and their patients, stated Dr. Tiago Reis Marques, CEO of Pasithea Therapeutics.
  • Current treatments have limited success and up to 30% of patients with depression do not respond to consecutive trials of antidepressant treatment.
  • Due to some risks associated with this drug, patients treated in outpatient settings must be enrolled in a specific program.
  • Pasithea Therapeutics Corporation is a U.S. biotechnology company focused on the research and discovery of new and effective treatments for psychiatric and neurological disorders.

Pasithea Therapeutics Launches In-Home Intravenous Ketamine Therapy in Major U.S. Cities, Expanding its International Footprint

Retrieved on: 
Wednesday, November 17, 2021
Patient, Patient safety, Social isolation, Anesthesia, Anxiety, CEO, Disorder, Forward-looking statement, Company, Population, Lists of diseases, Post-traumatic stress disorder, Psychopharmacology, Ketamine, SEC, IV, Food, KTTA, Psychiatry, City, Food and Drug Administration, Nasdaq, MIAMI, Research, GLOBE, Biotechnology, Depression, Pasithea (Charites), Motivation, Therapy, Privacy, Fatigue, Pharmaceutical industry

MIAMI BEACH, Fla., Nov. 17, 2021 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (Nasdaq: KTTA) (“Pasithea” or the “Company”), a novel biotechnology company focused on the research and discovery of new and effective treatments for psychiatric and neurological disorders, today announced that its wholly owned subsidiary, Pasithea Clinics, commenced clinical operations, offering in-home intravenous (“IV”) ketamine therapy to patients suffering from treatment-resistant mental health issues. Initially, the treatment will be offered in New York City, Los Angeles, San Diego, and San Francisco and will expand nationwide in the coming months.

Key Points: 
  • Ketamine, when used at sub-anesthetic doses, has been shown to be highly effective in treating some psychiatric disorders.
  • Through our mobile clinics, patients benefit from receiving the ketamine therapy in the privacy and comfort of their own homes.
  • With patient safety as our top priority, all ketamine treatments will be delivered by board-certified medical professionals.
  • This launch is an important stepping stone in expanding our international footprint in this space, stated Dr. Tiago Reis Marques, CEO of Pasithea Therapeutics.

Awakn Life Sciences Signs MOU with NHS (Devon Partnership NHS Trust) and University of Exeter with a View of Increasing Access to Psychedelic-Assisted Psychotherapy in the UK

Retrieved on: 
Tuesday, November 16, 2021
Eli Lilly and Company, University, News, III, KARE, Psychiatry, The American Journal of Psychiatry, Devon Partnership NHS Trust, Clinical trial, Russell Group, Depression, FSE, Public opinion, DPT, CEO, University of Exeter, Autism, SEDAR, Phrase, Research, Learning, UoE, Forward-looking statement, Ketamine, AUD, Intention, Perception, Partnership, American Journal, Acquisition, Mental health, Biotechnology, Company, Awareness, Person, MOU, Therapy, NHS, Addiction, Psychopharmacology, Review, MDMA, Patient, NEO, Pharmaceutical industry, Security (finance)

With a Focus on Bringing the KARE Phase II a/b Trial (Ketamine-Assisted Psychotherapy for Alcohol Use Disorder) into Phase III

Key Points: 
  • The partnership establishes a framework and strategic relationship to assess NHS organizational readiness for ketamine-assisted psychotherapy.
  • The partnership will also assess how best to accelerate the on-label use of ketamine-assisted psychotherapy to treat AUD at scale.
  • "The signing of the MOU is an important milestone as mental health issues continue to exacerbate globally.
  • About Awakn Life Sciences Corp.
    Awakn Life Sciences is a biotechnology company with clinical operations, developing and delivering psychedelic therapeutics (medicines and therapies) to better treat addiction.

Pasithea Therapeutics Collaborates with Renowned Musician and Producer to Create Soundtracks for Ketamine Therapy

Retrieved on: 
Thursday, November 11, 2021
Johns Hopkins, Therapy, Lists of diseases, Royal Academy of Music (company), Food and Drug Administration, CEO, MIAMI, United Kingdom, Food, Emotion, Psychopharmacology, Research, Forward-looking statement, Ketamine, KTTA, DJ, Biotechnology, Company, GLOBE, Calita, SEC, Imperial College London, Post-traumatic stress disorder, Nasdaq, Patient, Royal Academy of Arts, Psychiatry, Pharmaceutical industry

Music and psychedelic therapy are true complements, and through our collaboration with DJ Carlita, we aim to improve the overall experience for our patients, stated Dr. Tiago Reis Marques, CEO of Pasithea Therapeutics.

Key Points: 
  • Music and psychedelic therapy are true complements, and through our collaboration with DJ Carlita, we aim to improve the overall experience for our patients, stated Dr. Tiago Reis Marques, CEO of Pasithea Therapeutics.
  • Carlita is a classically trained musician, graduated in cello from the Royal Academy of Music in London.
  • She has since evolved to become a producer and DJ, having played on the most important stages internationally since her debut.
  • Pasithea Clinics, a wholly owned subsidiary of Pasithea Therapeutics, recently opened its first ketamine therapy clinic in the United Kingdom and began administering intravenous ketamine therapy to patients.

Pasithea Therapeutics Corp. Establishes Scientific Advisory Board and Names Dr. Charles B. Nemeroff as Chair

Retrieved on: 
Tuesday, November 9, 2021
University, Coronavirus Scientific Advisory Board (Turkey), Therapy, Psychiatry, National academy, National Academy of Medicine, American Psychiatric Association, American College of Psychiatrists, Prospectus, MIAMI, Department, Lists of diseases, Psychopharmacology, Research, American, Anxiety, Forward-looking statement, SAB, Behavioural sciences, Mentorship, KTTA, Risk, North Carolina, Mental health, Biotechnology, Company, GLOBE, Brain & Behavior Research Foundation, Dell Medical School, SEC, APA, Ketamine, ACP, Nasdaq, Patient, American College, Pharmaceutical industry

Forming a strong Scientific Advisory Board is an important step in establishing credibility as we commence our programs.

Key Points: 
  • Forming a strong Scientific Advisory Board is an important step in establishing credibility as we commence our programs.
  • We are thrilled to welcome Prof. Nemeroff, whose achievements in psychiatry and neuropsychopharmacology make him an ideal candidate to lead this important group.
  • I am honored to join and chair Pasithea Therapeutics Scientific Advisory Board.
  • Prof. Charles B. Nemeroff, M.D., Ph.D., is a Professor and Chair of the Department of Psychiatry and Behavioral Sciences at the University of Texas Dell Medical School and Matthew P. Nemeroff Endowed Chair.

Adhera Therapeutics Announces Appointment of Dr. Zahed Subhan to Board of Directors

Retrieved on: 
Monday, November 8, 2021
Aston, Neurology, Therapy, Type, Russell, Acquisition, Urology, Solution, Rouge, Business development, Board of directors, University of Leeds, University of West London, School, Bristol Myers Squibb, DuPont (1802–2017), Neuroscience, European, Russell Group, MBA, LLB, Pharmacology, USA, Biotechnology, NASH, GLOBE, Psychopharmacology, FDA, BS, Amgen, Psychology, Psychiatry, CEO, University of Bradford, Lists of diseases, Research university, Sale, Marketing, Drug discovery, Clinical research, ATRX, University, Drexel University, EMA, Aston University, Board, Sanofi, Drug development, Pharmaceutical industry, Fine chemical, Medicine

Baton Rouge, LA, Nov. 08, 2021 (GLOBE NEWSWIRE) -- Adhera Therapeutics, Inc. (OTCPK: ATRX) ("Adhera" or the "Company"), a clinical stage biopharmaceutical company, is pleased to announce the appointment of Zahed Subhan, BS MS PhD MBA LLB, to the Companys Board of Directors.

Key Points: 
  • Baton Rouge, LA, Nov. 08, 2021 (GLOBE NEWSWIRE) -- Adhera Therapeutics, Inc. (OTCPK: ATRX) ("Adhera" or the "Company"), a clinical stage biopharmaceutical company, is pleased to announce the appointment of Zahed Subhan, BS MS PhD MBA LLB, to the Companys Board of Directors.
  • Dr. Subhan is an international pharmaceutical and biotechnology executive with more than 30 years experience in the United States, United Kingdom, European Union, and Asia.
  • He is highly proficient in all phases of drug development with expertise in neurology, psychiatry, oncology, cardiovascular, urology and metabolic disease therapeutic areas.
  • Dr. Subhan has authored 40+ peer-reviewed papers published in academic journals on the topics of clinical pharmacology and business.

Pasithea Therapeutics Announces Successful Treatment of First Patients in the UK with Ketamine Infusion Therapy

Retrieved on: 
Wednesday, October 27, 2021
ZEN, Depression, Post-traumatic stress disorder, Research, Biotechnology, Ketamine, IV, KTTA, Patient, Food, Lists of diseases, SEC, Forward-looking statement, Psychopharmacology, Company, Mental health, CEO, MIAMI, Psychiatry, Nasdaq, Therapy, Pasithea (Charites), Food and Drug Administration, GLOBE, Pharmaceutical industry

In sub-anesthetic doses, ketamine has shown to be highly effective at treating some psychiatric disorders, such as treatment-resistant depression and post-traumatic stress disorder.

Key Points: 
  • In sub-anesthetic doses, ketamine has shown to be highly effective at treating some psychiatric disorders, such as treatment-resistant depression and post-traumatic stress disorder.
  • Today, we are thrilled to announce that we administered our first IV ketamine infusion therapy to patients with treatment-resistant depression, stated Dr. Tiago Reis Marques, CEO of Pasithea Therapeutics.
  • This is a significant milestone for Pasithea Clinics and for patients in the U.K. suffering with mental health conditions.
  • We are excited to continue providing treatment to patients deemed eligible to receive it, concluded Dr. Reis Marques.

Pasithea Therapeutics Opens its First Ketamine Therapy Clinic in the United Kingdom

Retrieved on: 
Thursday, October 14, 2021
ZEN, People, World, Psychopharmacology, Common stock, World Health Organization, Lists of diseases, Nasdaq, Ketamine, Private, MIAMI, Pharmacy, Pharmacist, KTTA, Baker Street, SEC, United Kingdom, Patient, Dermatology, Food and Drug Administration, Holborn, GLOBE, Food, Mental health, Biotechnology, Forward-looking statement, Company, Psychotherapy, CEO, IV, Psychiatry, Nutritionist, Post-traumatic stress disorder, Therapy, Research, Pasithea (Charites), Depression, Anesthesia, Pharmaceutical industry

MIAMI BEACH, Fla., Oct. 14, 2021 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (Nasdaq: KTTA) (“Pasithea” or the “Company”), a novel biotechnology company focused on the research and discovery of new and effective treatments for psychiatric and neurological disorders, today announced that its wholly owned subsidiary, Pasithea Clinics, has partnered with ZEN Healthcare to offer intravenous (“IV”) ketamine therapy to patients suffering from treatment-resistant mental health issues. Initially, the treatment will be offered in Knightsbridge, London, beginning October 2021.

Key Points: 
  • Pasithea Clinics has clinic partnerships both in the United States and in the United Kingdom to provide IV ketamine treatment.
  • In the U.S., it has partnered with The IV Doc, Inc., to provide in-home IV ketamine infusions.
  • This launch marks a significant milestone for Pasithea Clinics and for patients in the U.K. suffering with mental health conditions.
  • Our highly trained professionals are taking an integrative approach that combines the IV ketamine infusion therapy with psychiatric support.

2021 Pardes Humanitarian Prize in Mental Health Awarded to Three Women Striving to Improve Treatment, Expand Access and Empower People with Psychiatric Illness

Retrieved on: 
Tuesday, September 28, 2021
Brain & Behavior Research Foundation, Autobiography, Epidemiology, MPH, Mental health, Johns Hopkins University, Founder, Creativity, Psychiatry, Bipolar disorder, Comorbidity, Madness, Thought, Behavior, Prejudice, Depression, Empowerment, Psychopharmacology, Suicide, CEO, Awareness, World, Leadership, Pardes, PTSD, Autism, Anxiety, Borderline personality disorder, ADHD, Disability, Pulitzer Prize, Lists of diseases, OCD, Method, Disease, Woman, Foundation, Sustainable development, Government, Trustee, GLOBE, Publication, Psychosis, Brain, Hope, Hospital, Board, African, Art, Forensic psychiatry, United States Public Health Service, Research, Ethics, Schizophrenia, Medicine, Residential care, Pharmaceutical industry, Medical device

New York, Sept. 28, 2021 (GLOBE NEWSWIRE) -- The Brain & Behavior Research Foundation today announced that three extraordinary women who are advocates for mental health and live with mental illness are the winners of the 2021 Pardes Humanitarian Prize in Mental Health.

Key Points: 
  • New York, Sept. 28, 2021 (GLOBE NEWSWIRE) -- The Brain & Behavior Research Foundation today announced that three extraordinary women who are advocates for mental health and live with mental illness are the winners of the 2021 Pardes Humanitarian Prize in Mental Health.
  • Three 2021 Pardes Honorary Prize Recipients were also announced and acknowledged for their groundbreaking work in mental health.
  • She has made a profound contribution to mental health awareness through her autobiography, An Unquiet Mind, detailing her own struggles.
  • Itfocuses public attention on the burden mental illness places on individuals and society and the urgent need to expand mental health services globally.

New Psychedelic Therapy Clinic Opens in Charleston

Retrieved on: 
Tuesday, August 31, 2021
Psilocybin, California Institute for Regenerative Medicine, Certification, Growth, California Institute of Integral Studies, Innerbloom, Anxiety, Research, Psychotherapy, Mental health, Depression, Psychopharmacology, Psychological pain, Suite, FDA, MDMA, Pharmaceutical industry, Medicine, Hospital

It is during these trying times that Innerbloom Healing Arts has opened its new clinic in Charleston, South Carolina helping to lay the groundwork of a psychedelic reawakening in the field of mental health.

Key Points: 
  • It is during these trying times that Innerbloom Healing Arts has opened its new clinic in Charleston, South Carolina helping to lay the groundwork of a psychedelic reawakening in the field of mental health.
  • Innerbloom aims to provide Charleston and its surrounding areas with a space of healing and growth through the use of psychedelic medicines and therapy.
  • It is a clinic that hopes to create a therapeutic environment that breaks down the walls of suffering and brings out one's inner-healer.The new psychedelic treatment clinic opens on September 1st, 2021, located at 103 Logan Street, Suite 300, Charleston, South Carolina, 29401.
  • To learn about the new programs and therapies being offered to Charleston, visit the website, www.innerbloomhealingarts.com , or call 843-405-7598 today.